WO2011050107A3 - Compositions and methods for delivery of therapeutic agents to the cns - Google Patents

Compositions and methods for delivery of therapeutic agents to the cns Download PDF

Info

Publication number
WO2011050107A3
WO2011050107A3 PCT/US2010/053439 US2010053439W WO2011050107A3 WO 2011050107 A3 WO2011050107 A3 WO 2011050107A3 US 2010053439 W US2010053439 W US 2010053439W WO 2011050107 A3 WO2011050107 A3 WO 2011050107A3
Authority
WO
WIPO (PCT)
Prior art keywords
cns
therapeutic agents
delivery
compositions
human
Prior art date
Application number
PCT/US2010/053439
Other languages
French (fr)
Other versions
WO2011050107A2 (en
Inventor
Francis C. Zeigler
Original Assignee
Cns Delivery Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cns Delivery Systems filed Critical Cns Delivery Systems
Publication of WO2011050107A2 publication Critical patent/WO2011050107A2/en
Publication of WO2011050107A3 publication Critical patent/WO2011050107A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/24—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/34—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/56—Porous materials, e.g. foams or sponges

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Public Health (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides compositions and methods for sustained delivery of therapeutic agents to the CNS, using a novel implant material composed of fibrillar collagen coated with human laminin, allowing increased implant biocompatibility to sustain more efficient delivery of therapeutic agents to the CNS, which is an improvement in the field of sustained delivery of therapeutic agents to the CNS. This composition can be implanted in the CNS where needed and will persist for long times with minimal tissue reaction. The compositions are fibrillar collagen porous matrices coated with human laminin, to treat resection cavities of CNS tumors, which can be used to provide a sustained release delivery vehicle for therapeutic agents including chemotherapeutic drugs or tumor-targeting human cells from cultures, such as human neural progenitor cells.
PCT/US2010/053439 2009-10-20 2010-10-20 Compositions and methods for delivery of therapeutic agents to the cns WO2011050107A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25311109P 2009-10-20 2009-10-20
US61/253,111 2009-10-20
US30640510P 2010-02-19 2010-02-19
US61/306,405 2010-02-19

Publications (2)

Publication Number Publication Date
WO2011050107A2 WO2011050107A2 (en) 2011-04-28
WO2011050107A3 true WO2011050107A3 (en) 2012-05-10

Family

ID=43900948

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/053439 WO2011050107A2 (en) 2009-10-20 2010-10-20 Compositions and methods for delivery of therapeutic agents to the cns

Country Status (1)

Country Link
WO (1) WO2011050107A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170304006A1 (en) * 2014-12-01 2017-10-26 Brainlab Ag Method for Determining the Structure of a Medical Implant for Replacing Removed Tissue

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020082698A1 (en) * 2000-09-18 2002-06-27 Parenteau Nancy L. Method for treating a patient using a cultured connective tissue construct
US20090069903A1 (en) * 2007-07-03 2009-03-12 Histogenics Corporation Method For Improvement Of Differentiation Of Mesenchymal Stem Cells Using A Double-Structured Tissue Implant
US20090142409A1 (en) * 2007-05-10 2009-06-04 Firestone Leigh H Extracellular Matrix Compositions for Tissue Regeneration

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020082698A1 (en) * 2000-09-18 2002-06-27 Parenteau Nancy L. Method for treating a patient using a cultured connective tissue construct
US20090142409A1 (en) * 2007-05-10 2009-06-04 Firestone Leigh H Extracellular Matrix Compositions for Tissue Regeneration
US20090069903A1 (en) * 2007-07-03 2009-03-12 Histogenics Corporation Method For Improvement Of Differentiation Of Mesenchymal Stem Cells Using A Double-Structured Tissue Implant

Also Published As

Publication number Publication date
WO2011050107A2 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
Chen et al. Nanoparticle delivery of stable miR-199a-5p agomir improves the osteogenesis of human mesenchymal stem cells via the HIF1a pathway
Crupi et al. Inflammation in tissue engineering: The Janus between engraftment and rejection
Tierney et al. The development of non-viral gene-activated matrices for bone regeneration using polyethyleneimine (PEI) and collagen-based scaffolds
EP2150612A4 (en) Hybrid soft tissue implants from progenitor cells and biomaterials
Stocco et al. Tailored PVA/ECM scaffolds for cartilage regeneration
Deng et al. Bioceramic scaffolds with antioxidative functions for ROS scavenging and osteochondral regeneration
WO2009102452A3 (en) Compositions and methods for implantation of adipose tissue and adipose tissue products
WO2006081435A3 (en) Method of providing readily available cellular material derived from cord blood, and a composition thereof
TW200633733A (en) Biomaterials for guided tissue regeneration and drug delivery
WO2011082038A3 (en) Improved reprogramming compositions
WO2008054466A3 (en) Delivery of biologically active materials using core-shell tecto (dendritic polymers)
HK1118577A1 (en) Rnai expression constructs rnai
NZ603913A (en) Method of engrafting cells from solid tissues
MX2021003552A (en) Implantable devices for cell therapy and related methods.
WO2004047747A3 (en) Compositions and methods for cell dedifferentiation and tissue regeneration
Aframian et al. Current status of the development of an artificial salivary gland
NZ591146A (en) Composition comprising mesenchymal stem cell aggregates wherein the D90 of said aggregates is less than 150 micomills
WO2006093857A3 (en) Method of providing readily available cellular material derived from peripheral blood and a composition thereof
WO2009134866A3 (en) Cell membrane engineering
WO2003099225A3 (en) Compositions for delivering nucleic acids to cells
ATE445417T1 (en) EX VIVO METHODS AND COMPOSITIONS FOR NUCLEIC ACID ADMINISTRATION
WO2011017143A3 (en) Compositions and methods of preparing alloreactive cytotoxic t cells
WO2010082787A3 (en) Pharmaceutical composition for bone-disease treatment or countering inflammation, comprising cartilage stem cells as an active principle
WO2010144698A3 (en) Methods, systems, and compositions for neuronal differentiation of multipotent stromal cells
Yin et al. The use of gene activated matrix to mediate effective SMAD2 gene silencing against hypertrophic scar

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10825630

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC, EPO FORM 1205A DATED 18.09.2012

122 Ep: pct application non-entry in european phase

Ref document number: 10825630

Country of ref document: EP

Kind code of ref document: A2